Last reviewed · How we verify
Atovaquone Proguanil and Artesunate Pyronaridine
Atovaquone Proguanil and Artesunate Pyronaridine is a Antimalarial combination Small molecule drug developed by Armed Forces Research Institute of Medical Sciences, Thailand. It is currently FDA-approved for Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi).
This combination drug uses atovaquone-proguanil to inhibit parasite mitochondrial function and pyronaridine-artesunate to generate reactive oxygen species and inhibit heme polymerization, together targeting multiple stages of malaria parasite development.
This combination drug uses atovaquone-proguanil to inhibit parasite mitochondrial function and pyronaridine-artesunate to generate reactive oxygen species and inhibit heme polymerization, together targeting multiple stages of malaria parasite development. Used for Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi).
At a glance
| Generic name | Atovaquone Proguanil and Artesunate Pyronaridine |
|---|---|
| Sponsor | Armed Forces Research Institute of Medical Sciences, Thailand |
| Drug class | Antimalarial combination |
| Target | Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atovaquone-proguanil works by disrupting the electron transport chain in Plasmodium mitochondria and inhibiting dihydrofolate reductase, while artesunate-pyronaridine acts through artemisinin-derived endoperoxide activation and quinoline-like mechanisms to damage parasite proteins and DNA. The combination provides synergistic activity against both drug-sensitive and drug-resistant malaria parasites across multiple life-cycle stages.
Approved indications
- Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi)
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atovaquone Proguanil and Artesunate Pyronaridine CI brief — competitive landscape report
- Atovaquone Proguanil and Artesunate Pyronaridine updates RSS · CI watch RSS
- Armed Forces Research Institute of Medical Sciences, Thailand portfolio CI
Frequently asked questions about Atovaquone Proguanil and Artesunate Pyronaridine
What is Atovaquone Proguanil and Artesunate Pyronaridine?
How does Atovaquone Proguanil and Artesunate Pyronaridine work?
What is Atovaquone Proguanil and Artesunate Pyronaridine used for?
Who makes Atovaquone Proguanil and Artesunate Pyronaridine?
What drug class is Atovaquone Proguanil and Artesunate Pyronaridine in?
What development phase is Atovaquone Proguanil and Artesunate Pyronaridine in?
What are the side effects of Atovaquone Proguanil and Artesunate Pyronaridine?
What does Atovaquone Proguanil and Artesunate Pyronaridine target?
Related
- Drug class: All Antimalarial combination drugs
- Target: All drugs targeting Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase
- Manufacturer: Armed Forces Research Institute of Medical Sciences, Thailand — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi)
- Compare: Atovaquone Proguanil and Artesunate Pyronaridine vs similar drugs
- Pricing: Atovaquone Proguanil and Artesunate Pyronaridine cost, discount & access